The Role of Iron in Neurodegeneration
暂无分享,去创建一个
[1] M. Barcikowska,et al. Does iron play a role in Parkinson's disease? , 1994 .
[2] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[3] H. Akiyama,et al. An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys , 1996, Brain Research.
[4] R. Radi,et al. Desferrioxamine inhibition of the hydroxyl radical-like reactivity of peroxynitrite: role of the hydroxamic groups. , 1995, Free radical biology & medicine.
[5] P. Thong,et al. Increased iron in the substantia nigra of 6-OHDA induced parkinsonian rats: a nuclear microscopy study , 1996, Brain Research.
[6] R. Ordidge,et al. Assessment of relative brain iron concentrations using T2‐weighted and T2*‐weighted MRI at 3 Tesla , 1994, Magnetic resonance in medicine.
[7] P. Kaheinen,et al. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. , 1997, European journal of pharmacology.
[8] J. Cadet,et al. Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain , 1992, Brain Research Bulletin.
[9] E. Hirsch,et al. Glutathione peroxidase, glial cells and Parkinson's disease , 1993, Neuroscience.
[10] D. Ben-shachar,et al. The Iron Chelator Desferrioxamine (Desferal) Retards 6‐Hydroxydopamine‐Induced Degeneration of Nigrostriatal Dopamine Neurons , 1991, Journal of neurochemistry.
[11] M. Woodruff,et al. Toxin-Induced Models of Neurological Disorders , 1994, Springer US.
[12] M. Weller,et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. , 1994, Journal of neural transmission. Supplementum.
[13] R. Crichton. Inorganic biochemistry of iron metabolism , 2001 .
[14] P. Ryvlin,et al. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. , 1995, Archives of neurology.
[15] P. Riederer,et al. Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases? , 1994, Journal of neurochemistry.
[16] G. Page,et al. MPTP toxicity in rat striatal slices: dopamine uptake alteration does not appear to be related to lipid peroxidation. , 1997, Toxicology.
[17] R. Kostrzewa. Highly selective neurotoxins : basic and clinical applications , 1998 .
[18] A. Barzilai,et al. Levodopa induces apoptosis in cultured neuronal cells—A possible accelerator of nigrostriatal degeneration in Parkinson's disease? , 1997, Movement disorders : official journal of the Movement Disorder Society.
[19] S. Konitsiotis,et al. Chronic Exposure to MPTP as a Primate Model of Progressive Parkinsonism: A Pilot Study with a Free Radical Scavenger , 1998, Experimental Neurology.
[20] E. Grasbon-Frodl,et al. Lazaroid Treatment Prevents Death of Cultured Rat Embryonic Mesencephalic Neurons Following Glutathione Depletion , 1996, Journal of neurochemistry.
[21] F. Jiménez-Jiménez,et al. Peripheral iron metabolism in patients with Parkinson's disease , 1994, Journal of the Neurological Sciences.
[22] C. Olanow. Attempts to obtain neuroprotection in Parkinson's disease , 1997, Neurology.
[23] R. Ordidge,et al. Increased iron‐related MRI contrast in the substantia nigra in Parkinson's disease , 1995, Neurology.
[24] A. Barzilai,et al. Dopamine–melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease , 1997, Neurochemistry International.
[25] W. S. Enochs,et al. Purified Human Neuromelanin, Synthetic Dopamine Melanin as a Potential Model Pigment, and the Normal Human Substantia Nigra: Characterization by Electron Paramagnetic Resonance Spectroscopy , 1993, Journal of neurochemistry.
[26] H. M. Swartz,et al. The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[27] O. Lindvall,et al. Tirilazad Mesylate Improves Survival of Rat and Human Embryonic Mesencephalic Neuronsin Vitro , 1997, Experimental Neurology.
[28] B. Coull,et al. Lazaroids. CNS pharmacology and current research. , 1995, Drugs.
[29] H. Allain,et al. Monoamine Oxidase B Inhibitors , 1996 .
[30] S. Hirai,et al. Inhibitory effects of bromocriptine on phospholipid peroxidation induced by DOPA and iron , 1995, Neuroscience Letters.
[31] K. Jellinger,et al. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. , 1995, Journal of neural transmission. Supplementum.
[32] Gallium‐transferrin binding in treated and untreated Parkinson's disease , 1997, Neuroreport.
[33] G. Dryhurst,et al. Iron- and manganese-catalyzed autoxidation of dopamine in the presence of L-cysteine: possible insights into iron- and manganese-mediated dopaminergic neurotoxicity. , 1998, Chemical research in toxicology.
[34] P Riederer,et al. Iron in the Parkinsonian substantia nigra. , 1997, Movement disorders : official journal of the Movement Disorder Society.
[35] M. Muenter,et al. Multi‐center study of Parkinson mortality with early versus later dopa treatment , 1987, Annals of neurology.
[36] S. Fahn,et al. Antiparkinsonian therapies and brain mitochondrial complex I activity , 1995, Movement disorders : official journal of the Movement Disorder Society.
[37] C. Clarke. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence , 1995, Movement disorders : official journal of the Movement Disorder Society.
[38] C. Cooper,et al. Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease. , 1996, Biochemical and biophysical research communications.
[39] W. Linert,et al. Spontaneous autoxidation of dopamine , 1995 .
[40] C. Marsden,et al. New insights into the cause of Parkinson's disease , 1992, Neurology.
[41] K. Jellinger,et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.
[42] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[43] S. Shimohama,et al. Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress , 1998, Annals of neurology.
[44] J. Edwardson,et al. Transferrin receptors in the Parkinsonian midbrain , 1994, Neuropathology and applied neurobiology.
[45] K. Jellinger,et al. Iron‐Melanin Complex in Substantia Nigra of Parkinsonian Brains: An X‐Ray Microanalysis , 1992, Journal of neurochemistry.
[46] J. Cooper,et al. Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement , 1992, Journal of neurochemistry.
[47] E. Parati,et al. The chemical characterization of melanin contained in substantia nigra of human brain. , 1992, Biochimica et biophysica acta.
[48] F. Ye,et al. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance , 1996, Movement disorders : official journal of the Movement Disorder Society.
[49] K. Jellinger,et al. The role of transition metals in the pathogenesis of Parkinson's disease , 1995, Journal of the Neurological Sciences.
[50] B. Bergamasco,et al. EPR investigations of the iron domain in neuromelanin. , 1997, Biochimica et biophysica acta.
[51] M. Barcikowska,et al. Iron in parkinsonian and control substantia nigra—A mössbauer spectroscopy study , 1996, Movement disorders : official journal of the Movement Disorder Society.
[52] B. Freeman,et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[53] C. Winterbourn,et al. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. , 1989, Biochemical pharmacology.
[54] C. Marsden,et al. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. , 1997, Journal of neural transmission. Supplementum.
[55] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[56] C. Olanow,et al. l‐(−)‐Desmethylselegiline, a Metabolite of Selegiline [l‐(−)‐Deprenyl], Protects Mesencephalic Dopamine Neurons from Excitotoxicity In Vitro , 1997, Journal of neurochemistry.
[57] K. Lange,et al. Neuroprotection by dopamine agonists. , 1994, Journal of neural transmission. Supplementum.
[58] Z. Qian,et al. Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders , 1998, Brain Research Reviews.
[59] K. Mizukawa,et al. Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. , 1993, Advances in neurology.
[60] T. Sarna,et al. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. , 1995, Biochimica et biophysica acta.
[61] S. Benkovic,et al. Isoforms of ferritin have a specific cellular distribution in the brain , 1994, Journal of neuroscience research.
[62] P. Riederer,et al. Intranigral injected iron progressively reduces striatal dopamine metabolism , 1994, Journal of neural transmission. Parkinson's disease and dementia section.
[63] F. Blandini,et al. Prospects of glutamate antagonists in the therapy of Parkinson's disease , 1998, Fundamental & clinical pharmacology.
[64] R M Henkelman,et al. MR of human postmortem brain tissue: correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease. , 1993, AJNR. American journal of neuroradiology.
[65] B. Ackrell,et al. Is complex II involved in the inhibition of mitochondrial respiration by N-methyl-4-phenylpyridinium cation (MMP+) and N-methyl-beta-carbolines? , 1993, Biochemical Journal.
[66] C D Marsden,et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. , 1991, Brain : a journal of neurology.
[67] N. Verbeke,et al. Free radical scavenging properties of apomorphine enantiomers and dopamine: Possible implication in their mechanism of action in parkinsonism , 1995, Journal of neural transmission. Parkinson's disease and dementia section.
[68] K. Marder,et al. Dietary iron, animal fats, and risk of Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[69] K. Lange,et al. Glutamatergic drugs in Parkinson's disease. , 1994, Life sciences.
[70] P. Hof,et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson’s disease cases , 1996, Acta Neuropathologica.
[71] R. Swerdlow,et al. Origin and functional consequences of the complex I defect in Parkinson's disease , 1996, Annals of neurology.
[72] Barry Halliwell,et al. Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.
[73] R. Villa,et al. Pharmacology of lazaroids and brain energy metabolism: a review. , 1997, Pharmacological reviews.
[74] E. Hall,et al. The 21-aminosteroids: Potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia , 1989 .
[75] J. Cadet. Free radicals and neurodegeneration , 1994, Trends in Neurosciences.
[76] B. A. Brooks,et al. Midbrain Dopaminergic Cell Loss in Parkinson's Disease and MPTP‐Induced Parkinsonism: Sparing of Calbindin‐D25k—Containing Cells a , 1992, Annals of the New York Academy of Sciences.
[77] A. Santagostino,et al. Mitochondrial toxicity of iron and the protective role of ferritin on dopaminergic PC12 cell line. , 1995, Toxicology in vitro : an international journal published in association with BIBRA.
[78] C. Olanow,et al. Progressive Changes in Striatal Dopaminergic Markers, Nigral Volume, and Rotational Behavior Following Iron Infusion into the Rat Substantia Nigra , 1994, Experimental Neurology.
[79] A. Benazzouz,et al. Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. , 1995, European journal of pharmacology.
[80] P. Riederer,et al. The possible role of iron in the etiopathology of parkinson's disease , 1993, Movement disorders : official journal of the Movement Disorder Society.
[81] A J Lees,et al. Dopamine agonists in Parkinson's disease: a look at apomorphine , 1993, Fundamental & clinical pharmacology.
[82] R. Klausner,et al. Iron-sulfur clusters as biosensors of oxidants and iron. , 1996, Trends in biochemical sciences.
[83] K. Jellinger,et al. The Neuropathologic Basis of Different Clinical Subgroups of Parkinson's Disease , 1991, Journal of neuropathology and experimental neurology.
[84] Douglas H. Smith,et al. The Potential of 21-Aminosteroids (Lazaroids) as Neuroprotective Therapies in CNS Injury , 1995 .
[85] E. Schon,et al. Nonidentical distribution of transferrin and ferric iron in human brain , 1988, Neuroscience.
[86] J. Hubble,et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease , 1995, Annals of neurology.
[87] M. Musicco,et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease , 1990, Neurology.
[88] C. Morris,et al. Brain iron homeostasis. , 1992, Journal of inorganic biochemistry.
[89] E. Hall,et al. Lazaroids: potent inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders , 1993 .
[90] M. Verity,et al. Mineral and Metal Neurotoxicology , 1996 .
[91] T. Sarna,et al. Antioxidant action of neuromelanin: the mechanism of inhibitory effect on lipid peroxidation. , 1995, Archives of biochemistry and biophysics.
[92] H. Schipper,et al. Astrocyte Mitochondria: A Substrate for Iron Deposition in the Aging Rat Substantia Nigra , 1998, Experimental Neurology.
[93] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[94] R. Watts. The role of dopamine agonists in early Parkinson's disease , 1997, Neurology.
[95] L. Friberg,et al. Speech localization using repetitive transcranial magnetic stimulation , 1994, Neurology.
[96] A. Napolitano,et al. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. , 1997, Journal of medicinal chemistry.
[97] A. K. Agarwal,et al. Free Radical‐Generated Neurotoxicity of 6‐Hydroxydopamine , 1995, Journal of neurochemistry.
[98] P. Barnéoud,et al. Neuroprotective effects of riluzole on a model of parkinson's disease in the rat , 1996, Neuroscience.
[99] D. Schroeder,et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease , 1996, Neurology.
[100] Russell J. Lewis,et al. 6-Hydroxydopamine and Related Catecholaminergic Neurotoxins , 1998 .
[101] R. Petersen,et al. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease , 1995, Movement disorders : official journal of the Movement Disorder Society.
[102] J. Joseph,et al. Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. , 1996, Free radical biology & medicine.
[103] C. Rice-Evans,et al. Desferrioxamine as a lipid chain‐breaking antioxidant in sickle erythrocyte membranes , 1990, FEBS letters.
[104] Blair Ford,et al. Antiparkinsonian Agents , 1998, CNS drugs.
[105] H. Verschueren,et al. Dopamine and iron induce apoptosis in PC12 cells. , 1997, Pharmacology & toxicology.
[106] E. Rosengren,et al. Neuromelanin of the Human Substantia Nigra: A Mixed‐Type Melanin , 1994, Journal of neurochemistry.
[107] Ryan J. Uitti,et al. Early Detection of Parkinson’s Disease , 1996, Drugs & aging.
[108] G. Bringmann,et al. Studies of the potentially endogenous toxin TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) in neuronal and glial cell cultures. , 1995, Journal of neural transmission. Supplementum.
[109] Y. Agid,et al. Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys , 1995, Brain Research.
[110] K. Jellinger,et al. Iron deposits in brain disorders , 1993 .
[111] W. H. Church,et al. Uric acid is reduced in the substantia nigra in parkinson's disease: Effect on dopamine oxidation , 1994, Brain Research Bulletin.
[112] N. Hattori,et al. An immunohistochemical study on α‐ketoglutarate dehydrogenase complex in Parkinson's disease , 1994 .
[113] J. Cooper,et al. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease , 1993, Brain Research.
[114] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[115] J. Jankovic,et al. (−)-Deprenyl protection of 1-methyl-4 phenylpyridium ion (MPP+)-induced apoptosis independent of MAO-B inhibition , 1997, Neuroscience Letters.
[116] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[117] H. M. Swartz,et al. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain , 1996, Neuroscience.
[118] L. Wiseman,et al. Selegiline: A Review of its Clinical Efficacy in Parkinson??s Disease and its Clinical Potential in Alzheimer??s Disease , 1995 .
[119] K. Tipton,et al. Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine , 1996, Journal of neurochemistry.
[120] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[121] W. H. Oertel,et al. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat , 1994, Neuroscience.
[122] H. Reichmann,et al. The TaClo concept: 1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline (TaClo), a new toxin for dopaminergic neurons. , 1995, Journal of neural transmission. Supplementum.
[123] Y. Agid,et al. Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson's Disease: An X‐Ray Microanalysis , 1991, Journal of neurochemistry.
[124] G. Vernet,et al. Metal Ions in Biology And Medicine , 2000 .
[125] R. Uitti,et al. Regional Metal Concentrations in Parkinson's Disease, Other Chronic Neurological Diseases, and Control Brains , 1989, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[126] M. Zigmond,et al. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. , 1997, Journal of neural transmission. Supplementum.
[127] K. Earle. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. , 1968, Journal of neuropathology and experimental neurology.
[128] Elizabeth C. Theil. Regulation of ferritin and transferrin receptor mRNAs. , 1990, The Journal of biological chemistry.
[129] R. Elble. Animal Models of Action Tremor , 2008, Movement disorders : official journal of the Movement Disorder Society.
[130] C. Marsden,et al. Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.
[131] E. Perry,et al. Oxidative Damage to Proteins, Lipids, and DNA in Cortical Brain Regions from Patients with Dementia with Lewy Bodies , 1998, Journal of neurochemistry.
[132] C. Marsden,et al. Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease , 1990, Journal of neurochemistry.
[133] T. Shima,et al. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. , 1997, Free radical biology & medicine.
[134] John X. Wilson,et al. Antioxidant defense of the brain: a role for astrocytes. , 1997, Canadian journal of physiology and pharmacology.
[135] W R Markesbery,et al. Oxidative stress hypothesis in Alzheimer's disease. , 1997, Free radical biology & medicine.
[136] H. Reichmann,et al. Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats. , 1995, Journal of neural transmission. Supplementum.
[137] K. Marder,et al. Systemic iron metabolism and mortality from Parkinson's disease , 1998, Neurology.
[138] M. Youdim,et al. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. , 1996, European journal of pharmacology.
[139] K. Jellinger,et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease , 1994, Neuroscience Letters.
[140] W. Kraus,et al. Original Papers , 1924, The Journal of neurology and psychopathology.
[141] David Oakes,et al. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α‐tocopherol , 1997 .
[142] Y. Agid. Levodopa: Is toxicity a myth? , 1998, Neurology.
[143] P Riederer,et al. Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains , 1991, Journal of neurochemistry.
[144] G. Poli. Free Radicals in Brain Pathophysiology , 2000 .
[145] M. Ebadi,et al. Oxidative stress and antioxidant therapy in Parkinson's disease , 1996, Progress in Neurobiology.
[146] C. Marsden,et al. Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia , 1992 .
[147] I. Strömberg,et al. Lazaroid‐enhanced survival of grafted dopamine neurons does not increase target innervation , 1998, Neuroreport.
[148] P. Riederer,et al. Mössbauer Spectroscopic Studies of Purified Human Neuromelanin Isolated from the Substantia Nigra , 1995, Journal of neurochemistry.
[149] R. Reiter,et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. , 1996, Life sciences.
[150] L. Packer,et al. Vitamin E in biological systems. , 1990, Advances in experimental medicine and biology.
[151] S. Fahn. Levodopa-Induced Neurotoxicity , 1997 .
[152] K. Marder,et al. Altered systemic iron metabolism in Parkinson's disease , 1997, Neurology.
[153] Anthony E. Lang,et al. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .
[154] M. Youdim,et al. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. , 1997, Pharmacology & toxicology.
[155] E. Hirsch,et al. Neuronal vulnerability in Parkinson's disease. , 1997, Journal of neural transmission. Supplementum.
[156] J C Rothwell,et al. Physiology and Anatomy of Possible Oscillators in the Central Nervous System , 2008, Movement disorders : official journal of the Movement Disorder Society.
[157] K. Jellinger,et al. Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism. , 1995, Journal of neural transmission. Supplementum.
[158] P. Brundin,et al. Lazaroids improve the survival of cultured rat embryonic mesencephalic neurones. , 1994, Neuroreport.
[159] E. Stopa,et al. Neural Heme Oxygenase-1 Expression in Idiopathic Parkinson's Disease , 1998, Experimental Neurology.
[160] K. Jellinger,et al. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. , 1996, Biochimica et biophysica acta.
[161] M. Smith,et al. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease , 1996, Brain Research.
[162] D. Mash,et al. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons , 1994, Annals of neurology.
[163] P. Riederer,et al. In Vitro Studies of Ferritin Iron Release and Neurotoxicity , 1998, Journal of neurochemistry.
[164] P D Griffiths,et al. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. , 1993, Dementia.
[165] P. Riederer,et al. Biochemical lesions of the nigrostriatal system by TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) and derivatives. , 1995, Journal of neural transmission. Supplementum.
[166] Charles J. Epstein,et al. Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease , 1995, Nature Medicine.
[167] E. Hirsch,et al. The density of [125I]-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease , 1997, Brain Research.
[168] A. Cooper,et al. Glutamate Antagonists for Parkinson’s Disease , 1998 .
[169] Y. Agid,et al. Is the Vulnerability of Neurons in the Substantia Nigra of Patients with Parkinson's Disease Related to Their Neuromelanin Content? , 1992, Journal of neurochemistry.
[170] Johannes Kornhuber,et al. Dopamine/glutamate interactions in Parkinson's disease , 1997, Neuroscience & Biobehavioral Reviews.
[171] J. Cano,et al. Involvement of iron in MPP+ toxicity in substantia nigra: protection by desferrioxamine , 1997, Brain Research.
[172] J. Valpuesta,et al. Ferritin is associated with the aberrant tau filaments present in progressive supranuclear palsy. , 1998, The American journal of pathology.
[173] Olanow Cw,et al. Metals and free radicals in neurodegeneration. , 1994 .
[174] D. Ben-shachar,et al. Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats , 1991, Journal of neurochemistry.
[175] D. Mash,et al. Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice , 1991, Experimental Neurology.
[176] D. Dexter,et al. Evaluation of the pro-oxidant and antioxidant actions of L-DOPA and dopamine in vitro: implications for Parkinson's disease. , 1996, Free radical research.
[177] H. Reichmann,et al. 1-Trichloromethyl-1,2,3,4-tetrahydro-beta-carboline, a new inhibitor of complex I. , 1995, Journal of neural transmission. Supplementum.
[178] N. Hattori,et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[179] U. Kang,et al. The Role of Glutathione in Dopaminergic Neuronal Survival , 1997, Journal of neurochemistry.
[180] Shoulson. Mortality in DATATOP: A Multicenter trial in early Parkinson's disease , 1998, Annals of neurology.
[181] J. Cano,et al. Neuroprotective Effect of the Iron Chelator Desferrioxamine Against MPP+ Toxicity on Striatal Dopaminergic Terminals , 1997, Journal of neurochemistry.
[182] J. Connor. Evidence for Iron Mismanagement in the Brain in Neurological Disorders , 1997 .
[183] J. Braughler,et al. The 21-aminosteroid inhibitors of lipid peroxidation: reactions with lipid peroxyl and phenoxy radicals. , 1989, Free radical biology & medicine.
[184] F. Ye,et al. Increasing striatal iron content associated with normal aging , 1998, Movement disorders : official journal of the Movement Disorder Society.
[185] F. Hefti,et al. Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.
[186] N. Hattori,et al. An immunohistochemical study on manganese superoxide dismutase in Parkinson's disease , 1997, Journal of the Neurological Sciences.
[187] A. Bol,et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration , 1989, Annals of neurology.
[188] C. W. Olanow,et al. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study , 1992, Brain Research.
[189] K. Takeshige,et al. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. , 1990, Biochemical and biophysical research communications.
[190] M. Beal,et al. The Role of Oxidative Processes and Metal Ions in Aging and Alzheimer’s Disease , 1997 .
[191] K. Tipton,et al. Advances in Our Understanding of the Mechanisms of the Neurotoxicity of MPTP and Related Compounds , 1993, Journal of neurochemistry.
[192] C. Olanow,et al. Neurodegeneration and Neuroprotection in Parkinson's Disease , 1996 .
[193] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[194] P. Riederer,et al. Iron in Central Nervous System Disorders , 2001, Key Topics in Brain Research.
[195] W. Linert,et al. 6-Hydroxydopamine, dopamine, and ferritin: a cycle of reactions sustaining Parkinson's disease? , 2000 .
[196] D. Perl,et al. Oxidative Stress with Emphasis on the Role of LAMMA in Parkinson’s Disease , 1997 .
[197] O. Rascol,et al. Glutamate antagonists and Parkinson's disease: A review of clinical data , 1997, Neuroscience & Biobehavioral Reviews.
[198] J. A. Weil,et al. An in vitro EPR study of the free-radical scavenging actions of the lazaroid antioxidants U-74500A and U-78517F. , 1995, Free radical biology & medicine.
[199] E. Floor,et al. Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay , 1998, Journal of neurochemistry.
[200] P. K. Tulsi,et al. Hydroxyl Free Radical (·OH) Formation Reflected by Salicylate Hydroxylation and Neuromelanin , 1993, Annals of the New York Academy of Sciences.
[201] M. Contin,et al. Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease , 1996, Clinical pharmacokinetics.
[202] J. Langston,et al. MPTP: A Dopaminergic Neurotoxin , 1997 .
[203] A. Hersey,et al. A method for the comparative assessment of antioxidants as peroxyl radical scavengers. , 1989, Biochemical pharmacology.
[204] S. Fahn,et al. Study of movement disorders and brain iron by MR. , 1987, AJR. American journal of roentgenology.
[205] P. Riederer,et al. The role of iron in the basal ganglion. , 1990, Advances in neurology.
[206] W. Koller. Neuroprotective Therapy for Parkinson's Disease , 1997, Experimental Neurology.
[207] N. Asp,et al. Iron nutrition in health and disease. , 1996 .
[208] C. Marsden,et al. Complex I, Iron, and ferritin in Parkinson's disease substantia nigra , 1994, Annals of neurology.
[209] P. Brundin,et al. Lazaroids improve the survival of grafted rat embryonic dopamine neurons. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[210] C. Marsden,et al. Decreased Ferritin Levels in Brain in Parkinson's Disease , 1990, Journal of neurochemistry.
[211] P. Thouvenot,et al. Effects of iron complexes on brain calcium homeostasis. , 1997, Annals of clinical and laboratory science.
[212] C. Parsons,et al. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents — preclinical studies , 1997, Neuroscience & Biobehavioral Reviews.
[213] D. Richardson,et al. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. , 1997, Biochimica et biophysica acta.
[214] P. Leigh,et al. Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex , 1997, Neuroscience Letters.
[215] A. Kupsch,et al. Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. , 1995, Neuroreport.
[216] D. Godin,et al. Parkinson's disease: A disorder due to nigral glutathione deficiency? , 1982, Neuroscience Letters.
[217] W. Linert,et al. Complex formation followed by internal electron transfer: the reaction between L-dopa and iron(III) , 1991 .
[218] R. Reiter. Oxidative damage in the central nervous system: protection by melatonin , 1998, Progress in Neurobiology.
[219] C. Olanow,et al. l‐Deprenyl Protects Mesencephalic Dopamine Neurons from Glutamate Receptor‐Mediated Toxicity In Vitro , 1997, Journal of neurochemistry.
[220] S. K. Han,et al. l‐DOPA Up‐Regulates Glutathione and Protects Mesencephalic Cultures Against Oxidative Stress , 1996, Journal of neurochemistry.
[221] M. Beal,et al. Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons , 1996, Nature Medicine.
[222] N. Hattori,et al. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys , 1994, Neuroscience Letters.
[223] J. Rinne,et al. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts , 1997, Journal of the Neurological Sciences.
[224] P. Jenner,et al. Understanding cell death in parkinson's disease , 1998, Annals of neurology.
[225] A. Kupsch,et al. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin , 1996, Neurochemistry International.
[226] C. Olanow,et al. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study , 1994, Brain Research.
[227] A. Schapira,et al. Evidence for mitochondrial dysfunction in Parkinson's disease—a critical appraisal , 2004, Movement disorders : official journal of the Movement Disorder Society.
[228] A. Cohen,et al. Current status of iron chelation therapy with deferoxamine. , 1990, Seminars in hematology.
[229] J. Poirier,et al. Effect of MPTP and l‐Deprenyl on Antioxidant Enzymes and Lipid Peroxidation Levels in Mouse Brain , 1995, Journal of neurochemistry.
[230] C. Ward,et al. Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[231] A. Lees,et al. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease , 1995, BMJ.
[232] J. Witztum,et al. Abnormal Iron Deposition Associated With Lipid Peroxidation in Transgenic Mice Expressing lnterleukin-6 in the Brain , 1998, Journal of neuropathology and experimental neurology.
[233] Y. Agid,et al. Toxic Effects of Iron for Cultured Mesencephalic Dopaminergic Neurons Derived from Rat Embryonic Brains , 1992, Journal of neurochemistry.
[234] P. Riederer,et al. Understanding Parkinson's disease. , 1997, Scientific American.
[235] C. Olanow,et al. Pathological evidence for oxidative stress in Parkinson's disease and related degenerative disorders , 1996 .
[236] C. Fall,et al. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. , 1997, Biochimica et biophysica acta.
[237] S. Mandel,et al. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. , 2000, Journal of neural transmission. Supplementum.
[238] F. Watt,et al. Increased Iron in the Substantia Nigra Compacta of the MPTP‐Lesioned Hemiparkinsonian African Green Monkey: Evidence from Proton Microprobe Elemental Microanalysis , 1994, Journal of neurochemistry.
[239] C. Olanow,et al. Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers , 1993, Journal of neuroscience research.
[240] P. Enrico,et al. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3-6-tetrahydropyridine (MPTP)-treated rat , 1993, Neuroscience Letters.
[241] R. Ramsay,et al. Biochemical Events in the Development of Parkinsonism Induced by 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine , 1987, Journal of neurochemistry.
[242] Y Agid,et al. Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[243] 望月 秀樹. Iron-melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture , 1993 .
[244] Y. Agid,et al. Distribution of 125I‐Ferrotransferrin Binding Sites in the Mesencephalon of Control Subjects and Patients with Parkinson's Disease , 1993, Journal of neurochemistry.
[245] Joseph S. Beckman,et al. Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease , 1997, The Journal of Neuroscience.
[246] J S Beckman,et al. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. , 1992, Archives of biochemistry and biophysics.
[247] J. Imlay,et al. Superoxide accelerates DNA damage by elevating free-iron levels. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[248] E. Hirsch,et al. Iron metabolism and Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[249] B. Hyman,et al. Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.
[250] J M Cooper,et al. Mitochondrial Dysfunction in Neurodegeneration , 1997, Journal of bioenergetics and biomembranes.
[251] R. Uitti,et al. Comparative Review of Dopamine Receptor Agonists in Parkinson’s Disease , 1996, CNS drugs.
[252] T. Schallert,et al. MRI, brain iron and experimental Parkinson's disease , 1992, Journal of the Neurological Sciences.
[253] K. Jellinger. Neuropathology of Movement Disorders , 1998 .
[254] B. Szende,et al. The neuroprotective and neuronal rescue effects of (—)-deprenyl , 1998 .
[255] P. Grattan-Smith,et al. The neurological syndrome of infantile cobalamin deficiency: Developmental regression and involuntary movements , 1997, Movement disorders : official journal of the Movement Disorder Society.
[256] A. Lin,et al. Neuroprotection by S‐nitrosoglutathione of brain dopamine neurons from oxidative stress , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[257] E. Grasbon-Frodl,et al. The lazaroid U-83836E improves the survival of rat embryonic mesencephalic tissue stored at 4°C and subsequently used for cultures or intracerebral transplantation , 1996, Brain Research Bulletin.
[258] P. Riederer,et al. Oxidative stress: Free radical production in neural degeneration , 1994 .
[259] A. Tomkins,et al. Diet, body size and micronutrient status in Parkinson's disease. , 1992, European journal of clinical nutrition.
[260] K. Jellinger,et al. Brain iron and ferritin in Parkinson's and Alzheimer's diseases , 1990, Journal of neural transmission. Parkinson's disease and dementia section.
[261] J. Connor,et al. Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions , 1995, Journal of neurochemistry.
[262] H. G. Kim,et al. Manganese: A transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of Parkinsonism , 1998, Neuroscience.
[263] P. Riederer,et al. Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. , 1996, Advances in neurology.
[264] R. A. Knight,et al. ASSESSMENT OF RELATIVE BRAIN IRON CONCENTRATIONS USING T-2-WEIGHTED AND T-2(ASTERISK)-WEIGHTED MRI AT 3-TESLA , 1994 .
[265] V. Quaresima,et al. Oxidation of desferrioxamine to nitroxide free radical by activated human neutrophils. , 1993, Free radical biology & medicine.
[266] J. Connor,et al. A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains , 1995, Journal of neurochemistry.
[267] G. Zeevalk,et al. Role of Oxidative Stress and the Glutathione System in Loss of Dopamine Neurons Due to Impairment of Energy Metabolism , 1998, Journal of neurochemistry.
[268] D. Radice,et al. Iron and Other Metals in Neuromelanin, Substantia Nigra, and Putamen of Human Brain , 1994, Journal of neurochemistry.
[269] A. Friedman,et al. Controversies about iron in parkinsonian and control substantia nigra. , 1997, Acta neurobiologiae experimentalis.
[270] C. Olanow,et al. Intranigral Iron Infusion as a Model for Parkinson’s Disease , 1994 .
[271] A. Hofman,et al. Dietary antioxidants and Parkinson disease. The Rotterdam Study. , 1997, Archives of neurology.